With the dedicated work of the Division’s outstanding faculty,
we continue to provide superior care at the USC University Hospital,
USC/Norris Cancer Hospital (Norris) and LAC+USC Healthcare Network
(LAC+USC). Concurrently, the Division has continued to expand
its academic activities. Through the dedication and guidance
of Enrique Ostrzega, M.D., Fellowship Program Director, and
Jerold Shinbane, M.D., Associate Program Director, the Division
of Cardiovascular Medicine continued, and in fact enhanced,
its strong and competitive fellowship program. Furthermore,
we have been awarded full accreditation for our Cardiac Electrophysiology.
Our mission is to make the Division one of the best in the
country. We need to work on the cohesiveness of the Division members and fellows,
to add relevant faculty (e.g. heart failure, imaging and EP) and to generate
additional NIH supported research. Although there are many hurdles, the
future is bright.
Researchers
Seek Way to Stem Atherosclerosis »
Several USC research teams have combined their diverse areas
of expertise – including engineering, pharmaceutical
sciences and cardiology – to study a novel strategy
for preventing atherosclerosis. The researchers, led by primary
investigator Tzung Hsiai, holder of the Robert G. and Mary
G. Lane Early Career Chair at the USC Viterbi School of Engineering,
include Enrique Cadenas, the Charles Krown/Alumni Professor
in Pharmaceutical Sciences at the USC School of Pharmacy,
and Howard Hodis, the Harry J. Bauer and
Dorothy Bauer Rawlins Professor of Cardiology at the Keck
School of Medicine of USC
Estrogen
therapy may slow advance of atherosclerosis »
Keck School of Medicine researchers believe that giving women
estrogen after menopause may help delay heart disease, and
they have begun a landmark study funded by the National Institute
on Aging, one of the National Institutes of Health, to put
their beliefs to the test. Howard N. Hodis,
the Harry J. Bauer and Dorothy Bauer Rawlins Professor of
Cardiology, leads the five-year, $9.8 million Early versus
Late Intervention Trial with Estradiol, or ELITE.
Study
shows diuretics more effective than newer drugs in stemming
heart problems
The latest results from the Anti-hypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial, or ALLHAT—which
compared therapies for the prevention of heart disease—were
published in the April 6 issue of the Journal of the American
Medical Association (JAMA). L. Julian Haywood,
professor of medicine in the division of cardiovascular medicine
at the Keck School, was one of the paper’s co-authors
and has served on ALLHAT’s steering committee.
|
«
Back to Departments
